AUPH
Aurinia Pharmaceuticals Inc
NASDAQ: AUPH · HEALTHCARE · BIOTECHNOLOGY
$15.72
-3.24% today
Updated 2026-06-05
Market cap
$2.26B
P/E ratio
8.12
P/S ratio
7.57x
EPS (TTM)
$2.16
Dividend yield
—
52W range
$7 – $19
Volume
1.3M
WallStSmart proprietary scores
69
out of 100
Grade: B
Buy
Investment rating
9.3
Growth
A+8.5
Quality
A9.5
Profitability
A+6.7
Valuation
B5/9
Piotroski F-Score
Moderate
2.4
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →203 stocks currently score above 75
Price targets
Analyst target
$17.00
+8.14%
12-Month target
$17.96
+14.25%
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy4 Buy3 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 100.00% — above average
+ ROE 52.54% — strong efficiency
+ Free cash flow $32.52M — positive
+ Revenue growth 24.40% QoQ
+ Debt/equity 0.12x — low leverage
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $134.03M | $175.51M | $235.13M | $283.06M | $298.30M |
| Net income | $-108.18M | $-78.02M | $5.75M | $287.20M | $34.35M |
| EPS | — | — | — | — | $2.16 |
| Free cash flow | $-79.82M | $-34.18M | $44.11M | $135.41M | $32.52M |
| Profit margin | -80.71% | -44.45% | 2.45% | 101.47% | 100.00% |
Peer comparison
Smart narrative
Aurinia Pharmaceuticals Inc trades at $15.72. representing a P/E of 8.12x trailing earnings. Our Smart Value Score of 69/100 indicates the stock is good. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 2.37, it sits in the grey zone. TTM revenue stands at $298.30M. with profit margins at 100.00%.
Frequently asked questions
What is Aurinia Pharmaceuticals Inc's stock price?
Aurinia Pharmaceuticals Inc (AUPH) trades at $15.72, on a P/E of 8.1x and a P/S of 7.6x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Aurinia Pharmaceuticals Inc overvalued?
Aurinia Pharmaceuticals Inc carries a Smart Value Score of 69/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read.
What is the price target of Aurinia Pharmaceuticals Inc (AUPH)?
The 12-month analyst consensus target is $17.00, about 8.1% above the current $15.72. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Aurinia Pharmaceuticals Inc's revenue?
Aurinia Pharmaceuticals Inc's trailing twelve-month revenue is $298.30M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Aurinia Pharmaceuticals Inc's Altman Z-Score is 2.37, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio7.57x
ROE52.54%
Beta1.43
50D MA$15.94
200D MA$14.69
Shares out0.13B
Float0.13B
Short ratio—
Avg volume1.3M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—